RxDoctor Payments Data

Donald Daly, PA

Medical · Flint, MINPI 1447359518

Payments from drug & device makers

$883in general payments, 2019–2025

Across 30 payments — averaging $29.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$281
  • Lundbeck LLC$243
  • Bayer$126
  • AbbVie$60
  • Takeda Pharmaceuticals U.S.A., Inc.$53
  • Johnson & Johnson$36
  • plus $84 from 4 others

What the payments were for

  • Food & beverage$883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$883 in reported general payments places this provider in the 60th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$1,293
Medicare patients
13
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole41$56,742
TrintellixVortioxetine Hydrobromide84$40,336
Paliperidone ErPaliperidone14$3,514
Aripiprazole45$2,474
Quetiapine Fumarate132$1,113
Atomoxetine Hcl15$895
Clonazepam125$756
Bupropion Hcl SrBupropion Hcl53$651
Buspirone Hcl64$648
Trazodone Hcl87$646
Quetiapine Fumarate ErQuetiapine Fumarate20$609
Oxcarbazepine21$560
Duloxetine Hcl40$512
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$379
Divalproex Sodium ErDivalproex Sodium23$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$281$56,74241 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$40,33684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 755 medical providers in Michigan.

Other medical in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →